Bionano Genomics, Inc. (BNGO): Price and Financial Metrics

Bionano Genomics, Inc. (BNGO): $2.93

0.10 (-3.30%)

POWR Rating

Component Grades








Add BNGO to Watchlist
Sign Up

Industry: Biotech




#326 of 356

in industry

BNGO Price/Volume Stats

Current price $2.93 52-week high $30.10
Prev. close $3.03 52-week low $2.79
Day low $2.89 Volume 400,500
Day high $3.03 Avg. volume 859,442
50-day MA $3.81 Dividend yield N/A
200-day MA $9.29 Market Cap 103.57M

BNGO Stock Price Chart Interactive Chart >


  • Value is the dimension where BNGO ranks best; there it ranks ahead of 57.63% of US stocks.
  • The strongest trend for BNGO is in Value, which has been heading up over the past 177 days.
  • BNGO ranks lowest in Quality; there it ranks in the 2nd percentile.

BNGO Stock Summary

  • For BNGO, its debt to operating expenses ratio is greater than that reported by just 12.13% of US equities we're observing.
  • In terms of volatility of its share price, BNGO is more volatile than 96.7% of stocks we're observing.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for BNGO comes in at -53.81% -- higher than that of just 10.26% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to BIONANO GENOMICS INC, a group of peers worth examining would be IBIO, NSPR, HLGN, NSTG, and SERA.
  • BNGO's SEC filings can be seen here. And to visit BIONANO GENOMICS INC's official web site, go to

BNGO Valuation Summary

  • BNGO's price/earnings ratio is -0.7; this is 102.62% lower than that of the median Healthcare stock.
  • Over the past 62 months, BNGO's EV/EBIT ratio has gone up 3.2.

Below are key valuation metrics over time for BNGO.

Stock Date P/S P/B P/E EV/EBIT
BNGO 2023-09-22 3.3 0.5 -0.7 -0.7
BNGO 2023-09-21 3.3 0.5 -0.7 -0.7
BNGO 2023-09-20 3.4 0.5 -0.7 -0.7
BNGO 2023-09-19 3.4 0.5 -0.7 -0.7
BNGO 2023-09-18 3.4 0.5 -0.7 -0.7
BNGO 2023-09-15 3.6 0.5 -0.8 -0.8

BNGO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BNGO has a Quality Grade of D, ranking ahead of 7.91% of graded US stocks.
  • BNGO's asset turnover comes in at 0.063 -- ranking 71st of 75 Measuring and Control Equipment stocks.
  • 500 - Internal server error

The table below shows BNGO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.063 0.333 -3.723
2021-03-31 0.082 0.336 -2.825
2020-12-31 0.230 0.326 -4.176
2020-09-30 0.248 0.369 -6.041
2020-06-30 0.352 0.344 -2.947
2020-03-31 0.402 0.312 -2.104

BNGO Price Target

For more insight on analysts targets of BNGO, see our BNGO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $11.50 Average Broker Recommendation 1.12 (Strong Buy)

Bionano Genomics, Inc. (BNGO) Company Bio

Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics. Its Saphyr system includes an instrument, chip consumables, reagents, and a suite of data analysis tools. The company's Bionano prep kits and labeling kits provide the critical reagents and protocols needed to extract and label high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

BNGO Latest News Stream

Event/Time News Detail
Loading, please wait...

BNGO Latest Social Stream

Loading social stream, please wait...

View Full BNGO Social Stream

Latest BNGO News From Around the Web

Below are the latest news stories about BIONANO GENOMICS INC that investors may wish to consider to help them evaluate BNGO as an investment opportunity.

Benchmarking Study Shows Streamlined Structural Variant Detection and High Concordance for OGM Compared to Chromosomal Microarray Analysis, the Global Standard in Genetic Disease Analysis

SAN DIEGO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of the first peer-reviewed benchmarking study to compare optical genome mapping (OGM) to the current global standard in molecular analysis of constitutional genetic disorders, chromosomal microarray analysis (CMA). The study evaluated the potential of OGM to measure all classes of variant types covered by CMA, including gains, losses, aneuploidy, triploidy and absence of heterozygo

Yahoo | September 28, 2023

Ticking Time Bombs: 3 Biotech Stocks to Dump Before the Damage Is Done

Investors should do their due diligence before investing in these three risky, unreliable and unprofitable biotech stocks.

Chandler Capital on InvestorPlace | September 26, 2023

Bionano Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that on September 18, 2023, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted an inducement award consisting of a non-qualified stock option to purchase 106,000 shares of common stock to Gülsen Kama, the Company’s new Chief Financial Officer, under the Company’s 2020 Inducement Plan, as amended. The Compensation Committee approved the award as an

Yahoo | September 22, 2023

Bionano Genomics, Inc. (BNGO) Upgraded to Buy: Here's What You Should Know

Bionano Genomics, Inc. (BNGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Yahoo | September 21, 2023

Bionano Announces Third OEM Partner has Received China NMPA Approval for DNA Isolation Products for IVD Use of OGM

Bionano original equipment manufacturing (OEM) partner Ecobono obtained reagent Class I registration and approval for Bionano’s DNA isolation kits for optical genome mapping (OGM) from China's National Medical Products Administration (NMPA)Reagents can be utilized for in vitro diagnostics (IVD) use in ChinaWith this NMPA registration, Ecobono can sell OGM reagents to independent clinical laboratories and Chinese hospitals SAN DIEGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasd

Yahoo | September 21, 2023

Read More 'BNGO' Stories Here

BNGO Price Returns

1-mo -23.90%
3-mo -53.57%
6-mo -72.10%
1-year -83.72%
3-year -52.74%
5-year -95.71%
YTD -79.93%
2022 -51.17%
2021 -2.92%
2020 148.39%
2019 -76.34%
2018 N/A

Continue Researching BNGO

Want to see what other sources are saying about Bionano Genomics Inc's financials and stock price? Try the links below:

Bionano Genomics Inc (BNGO) Stock Price | Nasdaq
Bionano Genomics Inc (BNGO) Stock Quote, History and News - Yahoo Finance
Bionano Genomics Inc (BNGO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!